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Mitochondrial dysfunction, inflammation, and mutant
bone morphogenetic protein receptor 2 (BMPR2)
are associated with pulmonary arterial hypertension
(PAH), an incurable disease characterized by pulmo-
nary arterial (PA) endothelial cell (EC) apoptosis,
decreased microvessels, and occlusive vascular
remodeling. We hypothesized that reduced BMPR2
induces PAEC mitochondrial dysfunction, promoting
a pro-inflammatory or pro-apoptotic state. Mice with
EC deletion of BMPR2 develop hypoxia-induced
pulmonaryhypertension that, incontrast tonon-trans-
genic littermates, does not reverse upon reoxygena-
tion and is associated with reduced PA microvessels
and lung EC p53, PGC1a and TFAM, regulators of
mitochondrial biogenesis, and mitochondrial DNA.
Decreasing PAEC BMPR2 by siRNA during reoxyge-
nation represses p53, PGC1a, NRF2, TFAM, mito-
chondrial membrane potential, and ATP and induces
mitochondrial DNA deletion and apoptosis. Reducing
PAEC BMPR2 in normoxia increases p53, PGC1a,
TFAM, mitochondrial membrane potential, ATP pro-
duction, and glycolysis, and induces mitochondrial
fission and a pro-inflammatory state. These features
are recapitulated in PAECs from PAH patients with
mutant BMPR2.
INTRODUCTION
Endothelial cells (ECs) are continually exposed to injurious stim-
uli that adversely affect their interaction with platelets and inflam-
matory cells, alter their permeability, dysregulate their inhibition
of smooth muscle cell (SMC) proliferation, and even induce
apoptosis (Park et al., 2013). The ability of ECs to withstand
these insults relies upon the energetic machinery of the mito-
chondria. The influence of reoxygenation following hypoxia
(hypoxia-reoxygenation) on EC mitochondrial function has596 Cell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc.been studied in many vascular beds, including the lung, where
the most profound alterations occur (Giedt et al., 2012). Com-
mon examples of hypoxia-reoxygenation include exposure to
and return from high altitude. Pathological conditions include
lung infections, acute respiratory distress syndrome in adults
and premature neonates (Matuschak et al., 1998), and adminis-
tration of oxygen during anesthesia and in the postoperative
setting. Chronic hypoxia-reoxygenation underlies recurrent pul-
monary thromboembolism and sleep apnea. In the vast majority
of individuals, adaptation to hypoxia-reoxygenation is not a
problem. However, failure of normal mitochondrial adaptation
to hypoxia-reoxygenation could play a role in EC dysfunction
related to pulmonary arterial hypertension (PAH) (Jilwan et al.,
2013), pulmonary edema, or inflammation causing fibrosis (Gill
et al., 2014).
Altered mitochondrial metabolism associated with glycolysis
was described in PAH (Archer et al., 2008; Michelakis et al.,
2002b; Ryan et al., 2013). Specific mitochondrial abnormalities
related to clinical PAH and experimental pulmonary hyper-
tension (PH) include induction of a pseudohypoxic state via
activation of hypoxia-inducible factor 1a (HIF1a), impaired mito-
chondrial-ER interaction, and mitochondrial fission (Fijalkowska
et al., 2010; Sutendra and Michelakis, 2014). Dysmorphic mito-
chondria with defects in the electron transport chain, lower res-
piratory chain coupling, and inefficient use of oxygen have also
been reported (Michelakis et al., 2002b; Xu et al., 2007). These
abnormalities were linked to the chronic inflammatory process
in PAH (Sutendra et al., 2011) and to the progressive expansion
of SMC-like cells that obliterate the vascular lumen (Teichert-
Kuliszewska et al., 2006).
Mitochondrial dysfunction has been most extensively investi-
gated in vascular SMCs (Michelakis et al., 2002a; Sutendra
et al., 2010). However, PAECs from PAH patients are also char-
acterized by aberrant mitochondrial function and a glycolytic
state (Masri et al., 2007; Xu et al., 2007), and EC dysfunction is
central to the pathological changes that increase pulmonary
vascular resistance. For example, vulnerability of PAECs to
apoptosis is related to loss of distal pulmonary vessels (Tei-
chert-Kuliszewska et al., 2006) and emergence of apoptosis-
resistant PAECs in advanced occlusive plexogenic lesions
(Sakao et al., 2009). EC dysfunction also impairs production of
factors such as apelin that repress SMC proliferation (Alastalo
et al., 2011; Kim et al., 2013).
PAEC dysfunction in PAH has been related to amutation in the
bone morphogenetic protein receptor 2 (BMPR2) gene, found in
approximately 70% of families with PAH (Deng et al., 2000; Lane
et al., 2000) and in 20% of sporadic cases of idiopathic (I) PAH.
Impaired BMPR2 signaling is linked to the propensity of PAECs
to apoptose (Alastalo et al., 2011; Teichert-Kuliszewska et al.,
2006) and to amplification of a pro-inflammatory state (Sawada
et al., 2014a). As reduced BMPR2 expression, independent of
a mutation, is a feature of PAH (Atkinson et al., 2002), we hypoth-
esized a direct link between abnormal activity of BMPR2 and
impaired mitochondrial function.
Since BMPR2 regulates peroxisome proliferator-activated
receptor-g (PPARg)-mediated gene transcription in ECs and
SMCs (Guignabert et al., 2009; Hansmann et al., 2008), we
postulated that the PPARg co-activator (PGC1a), which plays
a key role in mitochondrial biogenesis (Ryan et al., 2013), would
also be regulated by BMPR2. PGC1a dysfunction is linked to
various cardiovascular diseases (Rowe et al., 2010; Ryan et al.,
2013; Sawada et al., 2014b). Recent reports implicate the tumor
suppressor p53 in regulating PGC1a in neuroblastoma cells, car-
diomyocytes, and ECs (Aquilano et al., 2013; Shimasaki et al.,
2013; Villeneuve et al., 2013). PGC1a is also a co-activator of
the transcription factors NRF1/2, which control the expression
of genes encoding antioxidant enzymes and mtDNA replication,
such as the mitochondrial transcription factor A (TFAM) (Scar-
pulla, 2008).
In this study we investigated transgenic mice with deletion of
Bmpr2 in ECs, normal human PAECs with BMPR2 depleted by
siRNA, and PAECs from PAH patients with mutant BMPR2. Un-
der basal conditions, loss of PAEC BMPR2 causes an aberrant
increase in mitochondrial membrane potential and a pro-inflam-
matory state. However, during hypoxia-reoxygenation, reduced
BMPR2 decreases mitochondrial biogenesis and energy meta-
bolism and promotes mtDNA damage and EC apoptosis.
RESULTS
Mice with Bmpr2 Deleted in ECs Have Sustained PH
following Hypoxia-Reoxygenation Associated with
Mitochondrial Dysfunction
To establish a relationship between reduced BMPR2, mitochon-
drial dysfunction, and PH, we used transgenic mice in which
Bmpr2 was deleted in ECs (EC-Bmpr2/). These mice were
produced by breeding SCL-CreERTM, R26LacZfl/fl, and Bmpr2fl/fl
mice to create conditional EC-specific Bmpr2 knockout (KO)
mice following a 10-day injection of tamoxifen and were charac-
terized by our group (Spiekerkoetter et al., 2013). They show no
significant PH at baseline and only a modest increase, relative to
wild-type (WT) littermates, following chronic hypoxia, as judged
by right ventricular systolic pressure (RVSP) and right ventricular
hypertrophy (RVH) (Spiekerkoetter et al., 2013). However, we
now report a more impressive phenotype following an additional
mitochondrial challenge, reoxygenation following hypoxia.When
KO mice were returned to room air for 1 month after a prior
3-week exposure to chronic hypoxia (10%oxygen), they showed
a pronounced increase in RVSP when compared to WT mice,
where values normalized to pre-hypoxia control levels (Fig-Cure 1A). Consistent with this, KO mice had a markedly reduced
PA acceleration time (PAAT) assessed by transthoracic echocar-
diography (Figure S1A). WT mice showed only a modest reduc-
tion in PAAT after hypoxia-reoxygenation, perhaps slightly
overestimating PA pressure due to the limited sensitivity of
the technique (Urboniene et al., 2010). No differences were
observed in heart rate, cardiac output, or ventricular function
across genotypes or experimental conditions (Figures S1B–
S1D), indicating that the RV maintains contractility, despite the
higher RVSP. This would suggest that deletion of BMPR2 in
coronary artery ECs during hypoxia-reoxygenation does not
impact cardiac function during the time frame studied.
Consistent with the hemodynamic data, KO mice in hypoxia-
reoxygenation versus WT also showed persistent RVH (Fig-
ure 1B), enhanced muscularization of distal pulmonary arteries
(DPAs) (Figures 1C and S1E), and reduced number of DPAs
per 100 alveoli (Figure 1D). Since the severity of reduced DPAs
in both genotypes was similar after hypoxia (Spiekerkoetter
et al., 2013), our data suggest that the KOmice have an impaired
capacity to regenerate DPA. In fact, lung ECs isolated from KO
mice after hypoxia-reoxygenation versus WT mice showed a
pro-apoptotic phenotype, judged by increased caspase-3/7 ac-
tivity (Figure 1E). Migration of lung ECs from KO mice was
impaired (Figure S1F), as was tube formation in Matrigel (Fig-
ure S1G). These features are consistent with compromised
regeneration of DPAs in hypoxia-reoxygenation.
Abnormalities in PAECs and mitochondrial function were
linked. Compared to WT littermates, lung ECs from KO mice in
normoxia showed elevated reactive oxygen species (ROS) as-
sessed by dihydroethidium (DHE) and MitoSOX Red staining
(Figures 1F and 1G), indicating that the source of ROS was mito-
chondrial. The reduction in mitochondrial ROS during hypoxia-
reoxygenation was more pronounced in KO versus WT mice.
KO mice also showed an increase in mitochondrial membrane
potential (DJm) in normoxia, and a severe reduction following
hypoxia-reoxygenation (Figure 1H) as assessed by JC-1
or TMRE fluorescence. However, pulmonary artery SMCs
(PASMCs) isolated from EC-Bmpr2/ and WT mice showed a
similar reduction in DJm following hypoxia-reoxygenation
(Figure S1H).
To determine whether the changes in DJm reflected
altered mitochondrial biogenesis, we assessed protein levels
of PGC1a and of p53, a known regulator of PGC1a (Villeneuve
et al., 2013). p53 and PGC1a were increased as assessed by
immunoblot in cultured lung ECs of KO versus WT mice in nor-
moxia (Figures 1I and 1J); however, during hypoxia-reoxygena-
tion, p53 levels fell relative to WT controls, and PGC1a was
reduced below WT levels in lung ECs from the KO mice. Since
PGC1a directs mtDNA replication via the transcription factor
NRF2 and its target, TFAM (Virbasius and Scarpulla, 1994), we
assessed TFAM protein levels. Like PGC1a, it was increased in
lung ECs of KO versus WT mice in normoxia, but was reduced
after hypoxia-reoxygenation (Figure 1K).
p53 and PGC1a Related to Altered BMPR2 in Pulmonary
Artery ECs
To understand the mechanism linking loss of BMPR2 with
alteredmitochondrial function and to extend our findings beyond
the KO mouse, we carried out experiments on human PAECsell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc. 597
Figure 1. EC-Bmpr2–/– Mice Show Unresolved PH
EC-Bmpr2/ (KO) versus littermate WT mice were exposed to 3 weeks of hypoxia (10% O2) and 4 weeks reoxygenation in normoxia (hypoxia-reoxygenation,
Reoxy) or housed for 7 weeks in normoxia. We measured (A) RVSP, (B) right ventricular (RV) hypertrophy (weight of RV/left ventricle and septum) (RV/LV+S), (C)
muscularization of pulmonary arteries, percentage of fully or partially muscularized arteries at alveolar wall, and duct level (D) arteries at alveolar duct and wall
level per 100 alveoli.
(E–K) Lung ECs were isolated from these mice, and (E) apoptosis assessed by caspase-3/7 luminescence assay, (F) mitochondrial membrane potential (Dcm)
using the TMRE fluorescence probe, (G) mitochondrial ROS generation by MitoSOX, (H) total ROS by DHE fluorescence (DHE Fluor.). Representative
immunoblots and relative densitometric analysis of (I) p53, (J) PGC1a and BMPR2, and (K) TFAMwith b-actin as loading control. Bars representmean ±SEMof (A)
n = 5, WT/KO normoxia; n = 7, WT Reoxy; n = 10, KO Reoxy; (B) n = 4, WT; n = 3, KO normoxia ; n = 5, WT Reoxy; n = 7, KO Reoxy; (C–G) n = 3, (H) n = 9, (I) n = 6,
(J) n = 5, (K) n = 4. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, comparing genotypes under the same condition; #, ##, and ### indicate
p < 0.05, p < 0.01, and p < 0.001, respectively, comparing the same genotype across conditions. Analyses performed by two-way ANOVA and Bonferroni post
hoc or, as indicated by ‘‘(),’’ Neuman-Keuls. See also Figure S1.
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Figure 2. BMPR2 Regulates p53 and PGC1a
Representative immunoblots and densitometry of
commercially available human PAECs transfected
with (A) BMPR2 (B2) siRNA, (B) p53 siRNA, or (C) B2
and p53 siRNA or non-targeting (Con) siRNA and
exposed to hypoxia (0.5% O2) for 48 hr followed
by normoxia (21% O2) for 48 hr, i.e., hypoxia-
reoxygenation (Reoxy), or incubated in normoxia
(21% O2) for 96 hr.
(D–F) Dcm in PAECs transfected with (D) B2 siRNA,
(E) p53 siRNA, and (F) PGC1a (PGC) siRNA versus
Con siRNA was measured by fluorescence probes,
JC-1 (D and F), or TMRE (E).
(G–I) Caspase-3/7 luminescence measured in
PAECs transfectedwith (G) B2, (H) p53, or (I) PGC1a
siRNA versus non-targeting (Con) siRNA. Bars
represent mean ± SEM of (A) n = 5, (B–H) n = 3, and
(I) n = 4. Analyses as in legend to Figure 1; ‘‘()’’ re-
flects Tukey or Newman-Keuls post hoc test. See
also Figure S2.transfected with control non-targeting or BMPR2 siRNA. Levels
of BMPR2 mRNA and protein were reduced to about 20% of the
levels in PAECs transfected with control siRNA. The PAECs were
then eithermaintained in normoxia for 96 hr, in hypoxia (0.5%O2)
for 48 or 96 hr, or exposed to 48 hr of hypoxia followed by reoxy-
genation in normoxia for 48 hr.
Human PAECs transfected with BMPR2 siRNA versus control
siRNA showed increased p53 and PGC1a, whereas under hyp-
oxia-reoxygenation, a decrease in p53 and PGC1a below nor-
moxia levels was evident (Figure 2A). Depletion of BMPR2 by
siRNA resulted in an increase of p53 transcriptional activity un-
der normoxia and a decrease in response to hypoxia-reoxyge-
nation, paralleling our findings related to PGC1a and consistent
with transcriptional regulation of PGC1a by p53 (Figure S2A).
Importantly, downregulation of p53 by siRNA had no effect on
the level of BMPR2 (Figure S2B), indicating that p53 is down-
stream of BMPR2 signaling. Depletion of p53 by siRNA reducedCell Metabolism 21, 596PGC1a protein under both normoxia and
hypoxia-reoxygenation (Figure 2B), and
depletion of both BMPR2 and p53
reduced PGC1a protein (Figure 2C) and
mRNA (Figure S2B). All these data are
consistent with regulation of PGC1a by
p53. Surprisingly, despite the increase in
PGC1a protein with loss of BMPR2, there
was no elevation in PGC1a mRNA (Fig-
ure S2C). This suggests either that there
was impaired stability of the PGC1a
mRNA associated with loss of BMPR2
and enhanced p53 transcriptional activity,
or that the increase in PGC1a protein
associated with loss of BMPR2 is p53
dependent, but not transcriptionally regu-
lated. Also, it is possible, although less
likely, that while basal production of
PGC1a is p53 dependent, the augmenta-
tion that occurs with loss of BMPR2 is
related to a different mechanism.To evaluate whether the BMPR2-dependent regulation of p53
and PGC1a is relevant to non-PA ECs, we reduced BMPR2 in
human umbilical vein ECs (HUVECs) and found BMPR2-depen-
dent changes similar to those seen in PAECs (Figure S2D). We
established that HIF1a was upregulated during 48 and 96 hr of
hypoxia, but unaffected by loss of BMPR2 (Figure S2E). In
response to 48 or 96 hr of hypoxia p53 levels fell, but indepen-
dently of loss of BMPR2 (Figure S2F).
To test the relevance of this pathway to DJm, we reduced
BMPR2, p53, and PGC1a by siRNA in PAECs maintained in
normoxia or hypoxia-reoxygenation and determined DJm by
JC-1 and TMRE assays. Loss of BMPR2 increased DJm under
normoxia, and further reduced DJm during hypoxia-reoxyge-
nation compared to control siRNA-transfected PAECs (Fig-
ure 2D). Decreasing either p53 or PGC1a reduced DJm under
both normoxia and hypoxia-reoxygenation (Figures 2E and 2F).
In contrast, in human PASMCs, DJm did not increase with–608, April 7, 2015 ª2015 Elsevier Inc. 599
Figure 3. Reducing BMPR2 in Normoxia In-
duces an Inflammatory Response
PAECs were transfected with B2 or Con siRNA in
normoxia and hypoxia-reoxygenation (Reoxy) as
described for Figure 2.
(A) ROS measured by DHE fluorescence.
(B) ROS production by PAECs transfected with B2
or Con siRNA and treated with antimycin (AA,
10 mM) or vehicle (Veh) for 1 hr in normoxia.
(C and D) IL8 mRNA (C) and IL6 mRNA (D).
(E) BMPR2, IL6, and IL8 mRNA of PAECs trans-
fected with B2 or Con siRNA under normoxia and
AA treatment as in (B).
(F) BMPR2, TFAM, and IL8 mRNA levels of PAECs
transfected with B2 siRNA or B2+TFAM siRNA. All
mRNA normalized to b-actin; bars represent
mean ± SEM of n = 3 with analyses as in Figures 1
and 2.loss of BMPR2 in normoxia, but did significantly increase
in response to hypoxia-reoxygenation (Figure S2G). This is
consistent with studies showing hyperpolarized mitochondria
in PAH PASMCs (Sutendra and Michelakis, 2014) and
suggests loss of BMPR2 function and another ‘‘hit,’’ e.g., reox-
ygenation following hypoxia, are necessary to increase DJm in
PASMCs.
Since mitochondrial function reflected in DJm is related to EC
survival, we determined the impact of loss of BMPR2, p53, and
PGC1a on the pro-apoptotic state of PAECs by the caspase-3/
7 activity assay (Figures 2G–2I) as well as by Sub G1 FACS
analysis using propidium iodide (Figure S2H). Loss of BMPR2
significantly increased caspase activity and reduced the number
of viable cells in hypoxia-reoxygenation (Figures 2G and S2H).
Importantly, reducing p53 or PGC1a increased caspase activity
under both conditions (Figures 2H and 2I), suggesting a pro-sur-
vival role of p53 and PGC1a in PAECs as previously reported
(Heo et al., 2011). BrdU incorporation revealed no BMPR2-
dependent effect on proliferation in normoxia or hypoxia-reoxy-
genation (Figure S2I).600 Cell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc.Reduced BMPR2 in Normoxia
Creates a Pro-Inflammatory State in
Pulmonary Artery ECs
As in the lung ECs from KO mice, we
observed a significant increase in
ROS production in PAECs with loss of
BMPR2 under normoxia, whereas ROS
was reduced below normoxia levels in
response to hypoxia-reoxygenation in
both control and BMPR2 siRNA-treated
cells (Figure 3A). To confirm that the
increase in ROS resulting from loss of
BMPR2 under normoxia is mediated by
mitochondrial respiration, we pre-treated
BMPR2-depleted PAECs with antimycin,
a quinone analog that binds to cytochrome
b562 and blocks electron transport to
the ubiquinone in complex III. When pre-
treated with antimycin, the ROS generated
in response to reduced BMPR2 was nolonger apparent, and residual ROS was similar to that in control
cells treated with antimycin (Figure 3B). We assessed whether
the increase in mitochondrial ROS with depletion of BMPR2 in
PAECs could be mediating an increase in mRNA expression of
the pro-inflammatory cytokines interleukin 8 (IL8) and IL6 (Fig-
ures 3C and 3D). However, IL8 and IL6 were even further
increased by antimycin (Figure 3E). TFAMmay repair the mtDNA
(Julian et al., 2013) and attenuate the inflammasome response
involving IL8 and Toll-like receptor 9 (TLR9) as reviewed in
West et al. (2011). Consistent with this, repression of TFAM by
siRNA also further increased IL8 (Figure 3F). This suggests that
both the increase in ROS and in TFAMmitigate the inflammatory
response.
PGC1a Mediates Activation of NRF2 and TFAM in
Pulmonary Artery ECs: Impact on mtDNA
TFAM is essential for mtDNA replication as well as mainte-
nance and repair (Larsson et al., 1998). We documented only
a trend toward an elevation in TFAM in PAECs with loss
of BMPR2 during normoxia, but a marked reduction with
Figure 4. Reducing BMPR2 Causes mtDNA Deletion during Hypoxia-Reoxygenation Related to Reduced TFAM and Elevated Caspase
Activity
(A–C) Representative immunoblots and densitometry for TFAM in PAECs transfected under normoxia or hypoxia-reoxygenation (Reoxy) with (A) B2, (B) PGC1a
(PGC), and (C) NRF2 siRNA, versus Con siRNA.
(D) Confocal images of mitochondrial morphology, fragmentation index, and total number as determined by MitoTracker Green staining under conditions of (A).
(E–F) Total mtDNA/nuclear DNA (18S) (E). mtDNA 4,977-bp deletion shown as a 352-bp amplicon on a 2% agarose gel (F) detected by qRT-PCR (G) after
transfection of B2 siRNA.
(H) PAECs transfected with TFAM (TF) versus Con siRNA. Representative immunoblot on right and apoptosis assessed by caspase activity under normoxia and
Reoxy. Bars represent mean ± SEM of n = 3 with analyses as in Figure 1. See also Figure S3.
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Figure 5. Loss of BMPR2 Alters Mitochondrial Function and Glucose Utilization of Pulmonary Artery ECs
Oxygen consumption rates of human PAECs transfected with B2 siRNA or non-targeting (Con) siRNA as described in Figure 2. (A) Baseline and (B)
maximal respiration following FCCP treatment; (C) spare respiratory capacity and (D) derived mitochondrial ATP production. Extracellular acidification rates
were measured to determine (E) aerobic glycolysis and (F) glycolytic reserve after sequential treatment with 10 mM glucose and 1 mM oligomycin. (G) Non-
glycolytic acidification after treatment with 100 mM 2-deoxyglucose under the same conditions. Bars represent mean ± SEM of (A)–(G) n = 3 with analyses as in
Figure 1.hypoxia-reoxygenation (Figure 4A). Decreasing either PGC1a
or NRF2 by siRNA reduced TFAM in normoxia and hypoxia-
reoxygenation (Figures 4B and 4C), whereas reducing NRF1
did not significantly affect TFAM levels (Figure S3A). This is
consistent with an increase in NRF2 transcriptional activity
with loss of BMPR2 in normoxia, and a decrease with loss of
BMPR2 and PGC1a with hypoxia-reoxygenation (Figures S3B
and S3C). Indeed, PGC1a siRNA reduces NRF2 transcriptional
activity during both normoxia and hypoxia-reoxygenation
(Figure S3C). The reduced TFAM in hypoxia-reoxygenation
was associated with loss of mtDNA (Figure 4D).
We identified mitochondrial fission in cells lacking BMPR2
under normoxia that was further enhanced in hypoxia-reoxy-
genation (Figure 4E). Since the balance between fission
and fusion is important in maintaining mitochondrial integrity
we investigated whether proteins known to regulate mitochon-
drial fusion, mitofusin 1 and 2, are reduced by BMPR2
signaling in PAECs. Interestingly, both mitofusin 1 and 2
were reduced, but only in hypoxia-reoxygenation, and not
aggravated by loss of BMPR2 (Figures S3D and S3E). Mitoph-
agy as assessed by LC3B protein level was also decreased
during hypoxia-reoxygenation and unaffected by reduced
BMPR2 (Figure S3F).
The somatic mutation rate of mtDNA is 10–20 times higher
than that of nuclear DNA (Taylor and Turnbull, 2005), and of
particular interest is the induction of a large 4,977-bp deletion
in mtDNA (DmtDNA4977) associated with cancer and neurode-
generative diseases (Chen et al., 2011). The presence of
DmtDNA4977 was assessed by PCR-based amplification of
a specific 352-bp amplicon that was validated by DNA
sequencing. In cells lacking BMPR2, an increase in the amplicon602 Cell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc.(Figure 4F) during hypoxia-reoxygenation was confirmed by
qPCR (Figure 4G). Reducing either PGC1a or TFAM under nor-
moxia or hypoxia-reoxygenation did not induce an increase in
DmtDNA4977 (Figure S3G) suggesting that additional factors
related to reduced p53 are required.
To determine whether loss of TFAM mimicked reduced
BMPR2 in producing a pro-apoptotic state, we assayed
caspase activity in PAECs transfected with TFAM siRNA
(Figure 4H). Indeed, PAECs with reduced TFAM showed
the same pro-apoptotic activity observed in cells with
reduced BMPR2, but only in hypoxia-reoxygenation, indi-
cating that loss of TFAM is necessary, but that induction
of apoptosis may require additional sequelae of reducing
PGC1a or p53.
To determine how reduced BMPR2might influence mitochon-
drial metabolism we carried out an extracellular flux assay, using
the Seahorse system described in the Supplemental Experi-
mental Procedures. Under normoxia, in keeping with a high
DJm and ROS generation in PAECs with reduced BMPR2, there
was an increase in oxygen consumption and derived mito-
chondrial ATP production. With hypoxia-reoxygenation, control
PAECs also showed heightened mitochondrial ATP produc-
tion and oxygen consumption, but not PAECs with reduced
BMPR2 (Figures 5A–5D). Increased glycolysis and glycolytic
reserve accompanied the increase in ATP production and oxy-
gen consumption in both normotoxic PAECs with loss of
BMPR2 and in control siRNA PAECs under hypoxia-reoxygena-
tion (Culic et al., 1997) (Figures 5E–5G). However, under hypoxia-
reoxygenation PAECs with reduced BMPR2 showed decreased
mitochondrial respiration (ATP production) and a diminished
glycolytic reserve.
Figure 6. Pulmonary Artery ECs from Patients with PAH Recapitulate the Pro-Inflammatory State in Normoxia and the Pro-Apoptotic State
with Hypoxia-Reoxygenation
PAECs from patients’ (PAH) or unused donors’ (Don) lungs as controls were incubated in normoxia or following the hypoxia-reoxygenation protocol (Reoxy).
(A–C) Representative immunoblots and quantitative densitometry with b-actin as loading control for p53 (A), PGC1a (B), and TFAM (C).
(D) Mitochondrial membrane activity by JC-1.
(E) ROS production by DHE fluorescence (DHE Fluor).
(F) The amplicon representing the 4,977-bp mtDNA deletion.
(G) Apoptosis by caspase activity.
(H and I) qRT-PCR for IL8 is shown in (H) and (I). To assess activation of IL8 by TLR9, the inhibitor (inh, ODN TTAGG) or vehicle (veh) was used in donor and in PAH
PAECs under normoxia (I).
Bars represent mean ± SEM, n = 3. Analyses as in Figure 1 with ‘‘()’’ indicating significance by Newman-Keuls (C, F, and G) or by Fisher LSD (H).The Response to BMPR2 siRNA Is Recapitulated in
Pulmonary Arterial ECs from Patients with a BMPR2
Mutation and PAH
To establish the clinical relevance of our findings to PAH pa-
tients, we assessed levels of BMPR2, p53, PGC1a, TFAM, and
the DmtDNA4977 in cultured PAECs from three PAH patients, all
with loss-of-function mutations of BMPR2, but with variable de-
grees of expression of the receptor (see Table S1 for character-
istics of the patients and controls). As in the BMPR2 siRNA
experiments, in PAECs from these patients versus controls,
p53, PGC1a, and TFAM (Figures 6A–6C) were elevated under
normoxia, and decreased in hypoxia-reoxygenation. Although
PAH PAECs showed an increase in DJm in normoxia and a
reduction in hypoxia-reoxygenation (Figure 6D), there were
no significant changes in ROS (Figure 6E). This suggests that
mitochondrial ROS production is not a consistent by-product
of the changes in mitochondrial metabolism related to mem-
brane potential. There was an increase in the DmtDNA4977 in
the PAH PAECs in hypoxia-reoxygenation (Figure 6F), and aCpro-apoptotic state evident by an increase in caspase activity
(Figure 6G).
In keeping with our findings in human PAECs with reduced
BMPR2, IL8 levels were increased in PAH PAECs in normoxia
and reduced in hypoxia-reoxygenation (Figure 6H). Interestingly,
IL8 levels were also elevated in donor PAECs in hypoxia-reoxy-
genation, perhaps reflecting the inflamed state of cells harvested
within 24 hr from our controls—unused donor lungs that were
excluded from transplant. As TLR9 can be activated by mtDNA
to initiate the innate immune system (Zhang et al., 2010), consis-
tent with an inflammasome response, we pre-treated PAH
PAECs with the TLR9 inhibitor (ODN TTAGG) and observed a
reduction in IL8 mRNA levels (Figure 6I).
DISCUSSION
Our studies using mice with BMPR2 deleted in lung ECs, human
PAECs with BMPR2 reduced by siRNA, and PAECs from PAH
patients with mutant BMPR2 establish a connection between aell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc. 603
Figure 7. Working Model: A Link be-
tween BMPR2 Signaling and Mitochondrial
Function
Loss of BMPR2 in PAECs during normoxia en-
hances mitochondrial biogenesis driven by p53,
PGC1a, NRF2, and TFAM, and increases DJm,
ATP, and glycolysis, leading to fission and causing
a pro-inflammatory state via interleukins such as
IL8. The increase in TFAM appears to partially
mitigate the increase in IL8. Loss of BMPR2 during
reoxygenation after hypoxia impairs p53-depen-
dent regulation of PGC1a and TFAM, reducesDJm
and ATP, and causes mitochondrial fission and
mtDNA deletion, inducing PAEC apoptosis leading
to loss of microvessels and aberrant prolifera-
tion of SM-like cells. Both inflammation and EC
apoptosis contribute to PAH (red arrows, up- or
downregulation; black arrows, sequela).known genetic abnormality linked to PAH and pathways that
promote mitochondrial dysfunction and mtDNA damage. Loss
of BMPR2 increases p53 transcriptional activity and PGC1a,
NRF2 and TFAM, DJm, mitochondrial ATP production, and
glycolysis. Mitochondria undergo fission, and there is increased
production of cytokines consistent with an inflammasome
response (Julian et al., 2013). Conversely, PAECs with loss of
BMPR2 respond to hypoxia-reoxygenation by repression of
the p53-PGC1a-NRF2-TFAM pathway, lowering of DJm, failure
to increase ATP production, and accumulation of a mtDNA dele-
tion (DmtDNA4977), resulting in a propensity to apoptosis (Fig-
ure 7). Both the decline in p53 transcriptional activity and the
loss of ATP can contribute to the apoptosis of PAECs.
Apoptotic PAECs are linked to the pathogenesis of PAH
related to loss of DPAs and to impaired production of EC factors
that repress SMC growth (Alastalo et al., 2011; Chun et al.,
2008). The ‘‘pro-inflammatory’’ PAEC phenotype with loss of
BMPR2 observed in these studies would facilitate infiltration
of immune cells that contribute to occlusion of the vessel lumen604 Cell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc.(Sawada et al., 2014a). The fact that sys-
temic ECs exhibit the same mitochondrial
abnormalities as PAECs in response to
loss of BMPR2 further reinforces the
importance of the pathway and is in
keeping with studies showing abnormal-
ities of microvessels in skeletal muscle
in patients with PAH (Potus et al., 2014).
The hypoxia-reoxygenation environment
of the lung relative to other vascular
beds would likely bring out the vulnera-
bility of PAECs. In fact, mutant BMPR2
also causes experimental PH in response
to hyperoxia-induced mitochondrial injury
(Fessel et al., 2013).
While our studies in PAH PAECs
focused on those with aBMPR2mutation,
reduced expression or function of the re-
ceptor has been related to all forms of
PAH (Atkinson et al., 2002), so we antici-
pate seeing similar abnormalities in generegulation and mitochondrial function. It appears that it is the re-
oxygenation following hypoxia, not hypoxia per se, that may be
the greater challenge to mitochondrial function, explaining why
the phenotype of unresolved PH is more striking than the rela-
tively mild exaggerated hypoxia-induced PH described in the
KO mice (Spiekerkoetter et al., 2013). This could mean that the
inability to reverse PH after a given perturbation may be more
tightly linked to a genetic abnormality than the nature of the insult
or the severity of the initial response to the perturbation. Alterna-
tively there are genotype-related changes that occur during hyp-
oxia independent of p53 and HIF1a we did not measure that un-
derlie the response to hypoxia-reoxygenation. While it is
possible that PH in the KO mice will regress over time, previous
studies in rats indicate that virtually all of the recovery takes
place in the first month of reoxygenation following hypoxia (Ra-
binovitch et al., 1981). Since mitochondrial changes in lung
ECs from KO versus WT are evident 1 month after hypoxia-reox-
ygenation and following passage in culture, the switch in cell
phenotype is likely permanent. It would be interesting to pursue
the role of epigenetics in maintaining this switch, since changes
in epigenetic factors are linked to altered mitochondrial meta-
bolism in PH fibroblasts (Li et al., 2011) and SMCs (Archer
et al., 2010). In view of the abnormalities in mitochondrial meta-
bolism described here and by others (Xu et al., 2007), therapies
like dichloroacetate that normalize glucose oxidation by inhibit-
ing pyruvate dehydrogenase kinasemay be effective in reversing
the phenotype of PAH PAECs (McMurtry et al., 2004; Michelakis
et al., 2002b).
The opposing responses to loss of BMPR2 in normoxia and
hypoxia-reoxygenation, i.e., heightened versus reduced tran-
scriptional activity of p53 and PGC1a, likely result from changes
in intracellular signaling (Davies et al., 2012; O’Prey et al., 2010;
Sawada et al., 2014a). Although Mizuno et al. (2011) reported an
interaction between p53 and HIF1a in SMCs, we could not
detect BMPR2-dependent regulation of HIF1a under normoxia,
hypoxia, or hypoxia-reoxygenation. Consistent with our findings
that lung EC dysfunction and apoptosis in EC-Bmpr2/ mice
are coupled to heightened muscularization of distal arteries,
p53 KO mice have increased proliferation of SMCs and develop
greater PH than WT mice during chronic hypoxia (Mizuno et al.,
2011). Conversely, activation of p53 by the MDM2 inhibitor
nutlin-3a prevents abnormal SMC proliferation associated with
hypoxia-induced PH (Mouraret et al., 2013).
Under normoxia, reduced BMPR2 in PAECs increases DJm
and ROS, consistent with similar results in PASMCs transfected
with mutant BMPR2 (Lane et al., 2011), but not in PASMCs with
BMPR2 siRNA, except under hypoxia-reoxygenation. NADPH
oxidases are important sources of ROS in ECs (Diebold et al.,
2009), but do not appear to account for the BMPR2-deficient
response. Reduced BMPR2 in PAECs caused heightened
expression of IL6 and IL8 that was not ROS-dependent, but
may relate to the changes in DJm and mitochondrial fission.
In mice with genetic ablation of EC-Bmpr2, attenuation of
leukocyte recruitment by blocking IL6 and IL8 receptors stops
progression of PH (Burton et al., 2011).
Several studies have shown that accumulation of DmtDNA4977
is due to oxidative damage, caused by proximity of mtDNA
to the ROS-producing respiratory chain and the lack of effective
repair mechanisms within mitochondria (Cheng et al., 2013).
In BMPR2-deficient PAECs exposed to hypoxia-reoxygenation,
accumulation of DmtDNA4977 is also seen with a decrease in
ROS production. Recent studies reported that reduced mitofu-
sin 2 in PASMCs contributes to disruption of mitochondria in
PAH (Bonnet et al., 2006; Ryan et al., 2013). We found reduced
mitofusin 2 and mitofusin 1 after hypoxia-reoxygenation, but
no BMPR2-related differences. It would be interesting to investi-
gate other genes such as optic atrophy 1 (OPA1) that regulate
mitochondrial fusion in cardiomyocytes (Duvezin-Caubet et al.,
2006), or dynamin-related protein 1 (DRP-1), a mediator of mito-
chondrial fission and apoptosis (Frank et al., 2001).
The pathway we identified, linking mitochondrial function to
PAEC survival and BMPR2 signaling, could be important in
developing therapies for PAH and other lung conditions with
EC dysfunction. Our data suggest that even mild forms of inter-
mittent hypoxia when coupled with dysfunction of BMPR2 may,
by compromising mitochondrial adaptation, promote the devel-
opment, persistence, or progression of PAH or cause other lung
disorders related to PAEC dysfunction. Addressing the impact ofCoxygen administration in the presence of BMPR2 dysfunction
would also be of potential clinical importance. The pathway we
have described may be relevant in other cells, e.g., in cancer,
where germline mutations of the BMP pathway have been iden-
tified (Howe et al., 2001). Conversely, a p53 mutation could be a
modifier of PAH.
EXPERIMENTAL PROCEDURES
Expanded experimental procedures are described in the Supplemental Infor-
mation. The Animal Care Committee of Stanford University approved all pro-
tocols, in keeping with the regulations of the American Physiological Society.
Procurement of the tissues from human subjects is approved by the Adminis-
trative Panel on Human Subjects in Medical Research at Stanford University
(IRB #350, Panel 6).
Mouse and Human Pulmonary Artery ECs
Primary murine lung ECs of WT or EC-Bmpr2/ mice were harvested from
lung tissue by elastase/collagenase digestion (Kim et al., 2011) and isolated
using CD31 antibody-coated magnetic beads (Alastalo et al., 2011). Primary
human PAECs were commercially obtained. Additional primary PAECs were
obtained from lungs removed at transplantation from PAH patients with a
known BMPR2 mutation, and from unused donor lungs as controls (patient
and donor characteristics in Table S1) (Sawada et al., 2014a). PAECs (pas-
sages 4–7) were grown in complete EC media. HUVECs were used at pas-
sages 3–5. For studies examining the response to hypoxia-reoxygenation, hu-
man PAECs, murine lung ECs, or HEK293T cells were incubated in normoxia
(21% O2, 5% CO2) for 96 hr or under hypoxia (0.5% O2, 5% CO2) in a hypoxic
workstation (Invivo2 400, Ruskinn Technology microaerobic system) for 48 hr
followed by re-incubation in normoxia (21% O2, 5% CO2) for 48 hr. Medium
was changed every 48 hr.
Mouse PASMCs
Mouse PASMCs were isolated using a modified elastase/collagenase diges-
tion protocol (Kim et al., 2011).
Mouse Model
Cell-specific inducible EC-Bmpr2/ mice were created in our laboratory as
described (Spiekerkoetter et al., 2013). Endothelial SCL-CRE ERT mice, with
a 50-endothelial SCL enhancer (7 to 0.9 kb) that directs expression to
endothelium, were crossed with Rosa26R mice and with Bmpr2fl/fl mice
created previously in our laboratory. Tamoxifen was given at 2 mg/day i.p.
for 10 days; after another 14 days, CRE activation was assessed, and a
deletion in Bmpr2 in ECs in lungs as well as all other vascularized tissues
was observed. The number of mice per experiment is indicated in the figure
legends. Mice (7–14 weeks of age) were housed in hypoxia (10% O2) for
3 weeks and recovered for 4 weeks in room air, or housed in room air for
7 weeks. RVSP and RVH, cardiac function and output, and pulmonary artery
acceleration time (PAAT) were measured (Hansmann et al., 2008). The heart
and lungs were perfused with PBS, the left lung fixed, and sections embedded
in paraffin for immunohistochemistry and morphometry. The right lung was
snap-frozen in liquid N2 and kept at 80C for protein and RNA extraction.
For EC isolation, lungs were perfused with PBS, transferred to EC medium
with 20% FBS, and incubated at 37C. For SMC isolation, lungs were
dissected directly after perfusion, and pulmonary arteries were cleared of
adventitia and kept in cold HBSS before elastase/collagenase treatment.
Reagents and Cellular Assays
Commercial reagents and kits used for cellular assays are described in the
Supplemental Information.
Immunofluorescence
Sections from formaldehyde-fixed, paraffin-embedded mouse lungs were de-
paraffinized and rehydrated. Epitope retrieval was performed, and sections
were then incubated with the primary antibodies against SMC actin (1:1,000)
and von Willebrand factor (vWF) (1:50).ell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc. 605
Tube Formation Assay
Cells were cultured in 5% FBS, and 10,000 cells were seeded on Matrigel. The
number of tubes and tube length were assessed after 8 hr by light microscopy
by two investigators blinded to the experimental group.
Migration by a Modified Boyden Chamber Assay
A total of 30,000 cells were seeded onto 0.2%-gelatin-coated microporous in-
serts, and cell migration was assessed after 16 hr as described (Alastalo et al.,
2011).
Cell Viability and Proliferation
PAECs exposed to hypoxia-reoxygenation were assessed for viability by pro-
pidium iodide staining and flow cytometry. Cell proliferation was assessed by
BrdU incorporation into PAECs, measured using a colorimetric cell prolifera-
tion ELISA.
Cignal Reporter Assay
HEK293T cells were transfected with NRF2 and p53 responsive luciferase
constructs that encode the firefly luciferase reporter gene under the control
of a promoter containing either the antioxidant response elements for NRF2
or the p53 response element. A Renilla construct encoding the Renilla
luciferase reporter gene under the control of a CMV promoter was used as
an internal control for normalizing transfection efficiency and monitoring cell
viability.
siRNA Transfection
siRNA specific for human BMPR2, PGC1a, p53, NRF1, NRF2, and TFAM or
siControl were transfected into PAECs by nucleofection or by lipofectamine.
Knockdown efficiency was determined by immunoblotting or qPCR.
Caspase Assay
Cells were incubated for 1 hr in caspase-3/7 luciferase reagent mix, and total
luminescence was measured in a plate reader.
Western Immunoblotting
Western immunoblotting was done as previously described (Sawada et al.,
2014a).
qRT-PCR
Total RNA was extracted and purified from cells. The quantity and quality of
RNA were determined by a spectrophotometer, and then RNA was reverse
transcribed to cDNA.
Mitochondrial Metabolism
Baseline mitochondrial function and mitochondrial stress response were
measured by oxygen consumption rate (OCR) using the Cell Mito Stress Kit
with an XF24 extracellular flux analyzer (Seahorse Bioscience). Glycolytic
capacity was measured using the XF Glycolysis Stress Test Kit (Seahorse
Bioscience) on the same device.
Mitochondrial Membrane Potential Assay
The mitochondrial membrane potential was determined using two fluorescent
methods: the JC-1 dye (50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolyl-
carbocyanine iodide) assay and the TMRE (tetramethylrhodamine, ethyl ester)
assay.
DHE Staining
Production of ROS was evaluated by DHE staining.
Mitochondrial ROS Assay
Murine lung ECs were seeded onto live cell imaging glass-bottom dishes
loaded with 100 nM MitoTracker Green FM (Molecular Probes) to stain mito-
chondria and 5 mM MitoSOX Red (Molecular Probes) to detect mitochondrial
superoxide. ROS production was normalized to cell number, and mitochon-
drial content was calculated as the ratio of MitoSOX to MitoTracker fluores-
cence (FMitoSOX/MitoTracker).606 Cell Metabolism 21, 596–608, April 7, 2015 ª2015 Elsevier Inc.Mitochondrial Morphometry
The mitochondrial fragmentation index assessed by Mito Tracker was defined
as ratio of fragmented mitochondria (dots) to tubular mitochondrial network
branch points (rods) per total number of mitochondria/cell as determined by
a semi-automated approach at the same contrast and brightness using Fiji
software.
DNA Isolation and PCR for Detection of mtDNA 4,977-bp Deletion
Total cellular DNA was isolated using DNeasy Blood & Tissue Kit (QIAGEN) for
PCR analysis. To detect the 4,977-bp deletion in mtDNAwe used the following
primers (Chen et al., 2011; Cheng et al., 2013): 1F, 50-AACCACAGTTT
CATGCCCATC-30; 1R, 50-TGTTAGTAAGGGTGGGGAAGC-30. TheWTmtDNA
primer sequences used were as follows: F, 50-GAAATGCCCCAACTAAATAC
TACCGT-30; R, 50-AATGAGTGAGGCAGGAGTCCG-30. The presence of the
4,977-bp deletion was indicated by the appearance of a 352-bp band (Chen
et al., 2011), verified by sequencing analysis.
Detection of Free mtDNA in Plasma of Mice
DNA was isolated from diluted plasma following centrifugation using DNeasy
Blood & Tissue Kit (QIAGEN). DNAwas eluted, the DNA solution further diluted,
and primers used to amplify mousemitochondrial cytochrome oxidase related
to nuclear DNA detected by 18S.
Statistical Analysis
All data are expressed as arithmetical mean ± SEM. Statistical significance was
determined first by two-way ANOVA followed by post hoc analysis (Bonferroni).
Soasnot tooverlookpotentially importantdifferences thatwerenot judged tobe
significant byBonferroni, we further subjected our data to theNewman-Keuls or
Fisher LSD multiple comparison tests as indicated in the figures and legends.
Two-sided unpaired t test analysis was used for comparison of two groups. A
p value of < 0.05 was considered significant. The number of experiments, ani-
mals per group, and the statistical test used are indicated in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2015.03.010.
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